Pulmonary hypertension in bronchopulmonary dysplasia

Progress in Pediatric Cardiology

Volumn 27, Issue 1-2, 2009, Pages 43-48

  Mourani, Peter M ^a   Mullen, Mary ^b   Abman, Steven H ^a  

^a Department of Pediatrics   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Angiogenesis; Bronchopulmonary dysplasia; Endothelin; Endothelin receptor antagonists; Inhaled nitric oxide; Prematurity; Prostacyclin; Pulmonary hypertension; Sildenafil

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; NIFEDIPINE; NITRIC OXIDE; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; UNIPROST;

ARTICLE; ASSISTED VENTILATION; BLOOD VESSEL REACTIVITY; CHILD CARE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART CATHETERIZATION; HUMAN; LONG TERM CARE; LOW DRUG DOSE; LUNG DYSPLASIA; LUNG HEMODYNAMICS; NONHUMAN; OXYGEN THERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; VASODILATATION;

EID: 70849094898     PISSN: 10589813     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ppedcard.2009.09.007     Document Type: Article

References (71)

1. Northway Jr. W.H., Rosan R.C., and Porter D.Y. Pulmonary disease following respiratory therapy of hyaline membrane disease. N Engl J Med 276 (1967) 357-368
2. Bland R.D., and Coalson J.J. Chronic lung disease in early infancy (2000), Marcel Dekker, NY
3. Jobe A.H., and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163 (2001) 1723-1729
4. Bancalari E., Abdenour G.E., Feller R., and Gannon J. Bronchopulmonary dysplasia: clinical presentation. J Pediatr 95 (1979) 819-823
5. Jobe A.H. The new BPD: an arrest of lung development. Pediatr Res 46 (1999) 641-643
6. Charafeddine L., D'Angio C.T., and Phelps D.L. Atypical chronic lung disease patterns in neonates. Pediatrics 103 (1999) 759-760
7. Rojas M.A., Gonzalez A., Bancalari E., et al. Changing trends in the epidemiology and pathogenesis of chronic lung disease. J Pediatr 126 (1995) 605-610
8. Smith V.C., Zupanic J.A.F., McCormick M.C., et al. Trends in more severe BPD rates between 1994-2002. J Pediatr 146 (2005) 469-473
9. Hussain A.N., Siddiqui N.H., and Stocker J.T. Pathology of arrested acinar development in post-surfactant BPD. Hum Pathol 29 (1998) 710-717
10. Bancarali E., and Gonzalez A. Clinical course and lung function abnormalities during development of chronic lung disease. In: Bland R.D., and Coalson J.J. (Eds). Chronic lung disease in early infancy (2000), Marcel Deffer, NY
11. Coalson J.J. Pathology of chronic lung disease of early infancy. In: Bland R.D., and Coalson J.J. (Eds). Chronic lung disease in early infancy (2000), Marcel Deffer, NY
12. Evans N.J., and Archer L.N.J. Doppler assessment of pulmonary artery pressure during recovery from hyaline membrane disease. Arch Dis Child 66 (1991) 802-804
13. Subhedar N.V., and Shaw N.J. Changes in pulmonary arterial pressure in preterm infants with chronic lung disease. Arch Dis Child 82 (2000) F243-F247
14. Fouron J.C., Le Guennec J.C., Villemant D., et al. Value of echocardiography in assessing the outcome of bronchopulmonary dysplasia of the newborn. Pediatrics 65 3 (1980) 529-535
15. Khemani E., McElhinney D.B., Rhein L., et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 120 6 (2007) 1260-1269
16. Coalson J.J. Pathology of chronic lung disease of early infancy. In: Bland R.D., and Coalson J.J. (Eds). Chronic lung disease of early infancy (2000), Marcel Dekker, NY 85-124
17. De Paepe M.E., Mao Q., Powell J., et al. Growth of pulmonary microvasculature in ventilated preterm infants. Am J Respir Crit Care Med 173 2 (2006) 204-211
18. Hussain A.N., Siddiqui N.H., and Stocker J.T. Pathology of arrested acinar development in postsurfactant BPD. Hum Pathol 29 (1998) 710-717
19. Jobe A.H., and Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 163 7 (2001) 1723-1729
20. Abman S.H. BPD: a vascular hypothesis. Am J Respir Crit Care Med 164 (2001) 1755-1756
21. Hislop A.A., and Haworth S.G. Pulmonary vascular damage and the development of cor pulmonale following hyaline membrane disease. Pediatr Pulmonol (1990) 152-161
22. Tomashefski J.F., Opperman H.C., and Vawter G.F. BPD: a morphometric study with emphasis on the pulmonary vasculature. Pediatr Pathol 2 (1984) 469-487
23. Abman S.H. Pulmonary hypertension in chronic lung disease of infancy. Pathogenesis, pathophysiology and treatment. In: Bland R.D., and Coalson J.J. (Eds). Chronic lung disease of infancy (2000), Marcel Dekker, NY 619-668
24. Jones R., Zapol W.M., and Reid L.M. Pulmonary artery remodeling and pulmonary hypertension after exposure to hyperoxia for 7 days. Am J Pathol 117 (1984) 273-285
25. Halliday H.L., Dumpit F.M., and Brady J.P. Effects of inspired oxygen on echocardiographic assessment of pulmonary vascular resistance and myocardial contractility in BPD. Pediatrics 65 (1980) 536-540
26. Abman S.H., Wolfe R.R., Accurso F.J., et al. Pulmonary vascular response to oxygen in infants with severe BPD. Pediatrics 75 (1985) 80-84
27. Goodman G., Perkin R., and Anas N. Pulmonary hypertension in infants with BPD. J Pediatr 112 (1988) 67-72
28. Mourani P.M., Ivy D.D., Gao D., and Abman S.H. Pulmonary vascular effects of inhaled NO and oxygen tension in BPD. Am J Respir Crit Care Med 170 (2004) 1006-1013
29. Jakkula M., Le Cras T.D., Gebb S., et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 279 (2000) L600-L607
30. Bhatt A.J., Pryhuber G.S., Huyck H., et al. Disrupted pulmonary vasculature and decreased VEGF, flt-1, and Tie 2 in human infants dying with BPD. Am J Respir Crit Care Med 164 (2000) 1971-1980
31. Walther F.J., Benders M.J., and Leighton J.O. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 90 6 (1992) 899-904
32. Abman S.H. Monitoring cardiovascular function in infants with chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 87 1 (2002) F15-F18
33. Kovesi T., Abdurahman A., and Blayney M. Elevated carbon dioxide tension as a predictor of subsequent adverse events in infants with bronchopulmonary dysplasia. Lung 184 1 (2006) 7-13
34. Mourani P.M., Ivy D.D., Rosenberg A.A., et al. Left ventricular diastolic dysfunction in bronchopulmonary dysplasia. J Pediatr 152 2 (2008) 291-293
35. Puchalski M.D., Lozier J.S., Bradley D.J., et al. Electrocardiography in the diagnosis of right ventricular hypertrophy in children. Pediatrics 118 3 (2006) 1052-1055
36. Yock P.G., and Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation 70 4 (1984) 657-662
37. Berger M., Haimowitz A., Van Tosh A., et al. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 6 2 (1985) 359-365
38. Currie P.J., Seward J.B., Chan K.L., et al. Continuous wave Doppler determination of right ventricular pressure: a simultaneous Doppler-catheterization study in 127 patients. J Am Coll Cardiol 6 4 (1985) 750-756
39. Skjaerpe T., and Hatle L. Noninvasive estimation of systolic pressure in the right ventricle in patients with tricuspid regurgitation. Eur Heart J 7 8 (1986) 704-710
40. Skinner J.R., Stuart A.G., O'Sullivan J., et al. Right heart pressure determination by Doppler in infants with tricuspid regurgitation. Arch Dis Child 69 2 (1993) 216-220
41. Mourani P.M., Sontag M.K., Younoszai A., et al. Clinical utility of echocardiography for the diagnosis and management of pulmonary vascular disease in young children with chronic lung disease. Pediatrics 121 2 (2008) 317-325
42. Arcasoy S.M., Christie J.D., Ferrari V.A., et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 167 5 (2003) 735-740
43. Yates A.R., Welty S.E., Gest A.L., et al. Myocardial tissue Doppler changes in patients with BPD. J Pediatr 152 (2008) 766-770
44. Drossner D.M., Kim D.W., Maher K.O., et al. Pulmonary vein stenosis: prematurity and associated conditions. Pediatrics 122 (2008) e656-e661
45. Groothuis J.R., and Rosenberg A.A. Home oxygen promotes weight gain in infants with bronchopulmonary dysplasia. Am J Dis Child 141 9 (1987) 992-995
46. Banks B.A., Seri I., Ischiropoulos H., et al. Changes in oxygenation with inhaled nitric oxide in severe bronchopulmonary dysplasia. Pediatrics 103 3 (1999) 610-618
47. Schreiber M.D., Gin-Mestan K., Marks J.D., et al. Inhaled nitric oxide in premature infants with the respiratory distress syndrome. N Engl J Med 349 22 (2003) 2099-2107
48. Kinsella J.P., Cutter G.R., Walsh W.F., et al. Early inhaled nitric oxide therapy in premature newborns with respiratory failure. N Engl J Med 355 4 (2006) 354-364
49. Ballard R.A., Truog W.E., Canaan A., et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N Engl J Med 355 4 (2006) 343-353
50. Channick R.N., Newhart J.W., Johnson F.W., et al. Pulsed delivery of inhaled nitric oxide to patients with primary pulmonary hypertension: an ambulatory delivery system and initial clinical tests. Chest 109 6 (1996) 1545-1549
51. Kitamukai O., Sakuma M., Takahashi T., et al. Hemodynamic effects of inhaled nitric oxide using pulse delivery and continuous delivery systems in pulmonary hypertension. Intern Med 41 6 (2002) 429-434
52. Ivy D.D., Parker D., Doran A., et al. Acute hemodynamic effects and home therapy using a novel pulsed nasal nitric oxide delivery system in children and young adults with pulmonary hypertension. Am J Cardiol 92 7 (2003) 886-890
53. Mourani P.M., Sontag M.K., Ivy D.D., and Abman S.H. Effects of long-term sildenafil treatment for pulmonary hypertension in infants with chronic lung disease. J Pediatr (2008) [Electronic publication ahead of print]
54. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 20 (2005) 2148-2157
55. Ghofrani H.A., Rose F., Schermuly R.T., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42 1 (2003) 158-164
56. Bhatia S., Frantz R.P., Severson C.J., et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78 10 (2003) 1207-1213
57. Baquero H., Soliz A., Neira F., et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117 4 (2006) 1077-1083
58. Humpl T., Reyes J.T., Holtby H., et al. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation 111 24 (2005) 3274-3280
59. Namachivayam P., Theilen U., Butt W.W., et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am J Respir Crit Care Med 174 9 (2006) 1042-1047
60. Rosenberg A.A., Kennaugh J., Koppenhafer S.L., et al. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J Pediatr 123 1 (1993) 109-114
61. Kojima T., Hattori K., Hirata Y., et al. Endothelin-1 has a priming effect on production of superoxide anion by alveolar macrophages: its possible correlation with bronchopulmonary dysplasia. Pediatr Res 39 1 (1996) 112-116
62. Allen S.W., Chatfield B.A., Koppenhafer S.L., et al. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension associated with acute hypoxic pulmonary vasoreactivity. Am Rev Respir Dis 148 (1993) 519-522
63. Rosenzweig E.B., Ivy D.D., Widlitz A., et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 46 4 (2005) 697-704
64. Benza R.L., Mehta S., Keogh A., et al. Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan. J Heart Lung Transplant 26 1 (2007) 63-69
65. Brownlee J.R., Beekman R.H., and Rosenthal A. Acute hemodynamic effects of nifedipine in infants with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res 24 2 (1988) 186-190
66. Johnson C.E., Beekman R.H., Kostyshak D.A., et al. Pharmacokinetics and pharmacodynamics of nifedipine in children with bronchopulmonary dysplasia and pulmonary hypertension. Pediatr Res 29 5 (1991) 500-503
67. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous epoprotenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 334 (1996) 296-302
68. Barst R.J., Maislin G., and Fishman A.P. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 99 9 (1999) 1197-1208
69. Zaidi A.N., Dettorre M.D., Ceneviva G.D., et al. Epoprostenol and home mechanical ventilation for pulmonary hypertension associated with chronic lung disease. Pediatr Pulmonol 40 3 (2005) 265-269
70. Rugolotto S., Errico G., Beghini R., et al. Weaning of epoprostenol in a small infant receiving concomitant bosentan for severe pulmonary arterial hypertension secondary to bronchopulmonary dysplasia. Minerva Pediatr 58 5 (2006) 491-494
71. Ivy D.D., Doran A.K., Smith K.J., et al. Short- and long-term effects of inhaled iloprost therapy in children with pulmonary arterial hypertension. J Am Coll Cardiol 51 2 (2008) 161-169